Long-term HbA1c variability and macro-/micro-vascular complications in type 2 diabetes mellitus: a meta-analysis update

G Sartore, E Ragazzi, R Caprino, A Lapolla - Acta diabetologica, 2023 - Springer
Aims The aim of the present study was to evaluate, by means of a meta-analysis approach,
whether new available data, appeared on qualified literature, can support the effectiveness …

Wearable and digital devices to monitor and treat metabolic diseases

A Keshet, L Reicher, N Bar, E Segal - Nature metabolism, 2023 - nature.com
Cardiometabolic diseases are a major public-health concern owing to their increasing
prevalence worldwide. These diseases are characterized by a high degree of interindividual …

Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning

S Lee, J Zhou, WT Wong, T Liu, WKK Wu… - BMC endocrine …, 2021 - Springer
Introduction Recent studies have reported that HbA1c and lipid variability is useful for risk
stratification in diabetes mellitus. The present study evaluated the predictive value of the …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population …

JV Mui, J Zhou, S Lee, KSK Leung, TTL Lee… - Frontiers in …, 2021 - frontiersin.org
Introduction: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and
dipeptidyl peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 …

Pioglitazone inhibits diabetes-induced atrial mitochondrial oxidative stress and improves mitochondrial biogenesis, dynamics, and function through the PPAR-γ/PGC …

Z Zhang, X Zhang, L Meng, M Gong, J Li… - Frontiers in …, 2021 - frontiersin.org
Background: Oxidative stress contributes to adverse atrial remodeling in diabetes mellitus.
This remodeling can be prevented by the PPAR-γ agonist pioglitazone via its antioxidant …

HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target

A Ceriello, G Lucisano, F Prattichizzo… - Cardiovascular …, 2022 - Springer
Background HbA1c variability has emerged as risk factor for cardiovascular diseases in
diabetes. However, the impact of HbA1c variability on cardiovascular diseases in subjects …

Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic …

S Lee, J Zhou, KSK Leung, AKC Wai… - … drugs and therapy, 2023 - Springer
Objective To compare the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) and
dipeptidyl peptidase-4 inhibitors (DPP4Is) on adverse outcomes in diabetic patients in Hong …

Diabetes knowledge predicts HbA1c levels of people with type 2 diabetes mellitus in rural China: a ten-month follow-up study

X Wang, B Tian, S Zhang, J Zhang, W Yang, J Li… - Scientific Reports, 2023 - nature.com
Improving diabetes self-management (DSM) is facing real-world challenges among people
with type 2 diabetes mellitus (T2DM) who have a low education level in resource-limited …

Risk of new-onset prostate cancer for metformin versus sulfonylurea use in type 2 diabetes mellitus: a propensity score–matched study

YHA Lee, J Zhou, JMH Hui, X Liu, TTL Lee… - Journal of the National …, 2022 - jnccn.org
Background: The aim of this study was to compare the risks of new-onset prostate cancer
between metformin and sulfonylurea users with type 2 diabetes mellitus (T2DM). Methods …

Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death

S Lee, J Zhou, CL Guo, WT Wong, T Liu… - Endocrinology …, 2021 - Wiley Online Library
Introduction The present study evaluated the application of incorporating non‐linear J/U‐
shaped relationships between mean HbA1c and cholesterol levels into risk scores for …